Immuron Limited (IMRN)

2,5200 -0,0200 (-0,79%) Alla chiusura: 04:00PM EDT

Immuron Limited

62 Lygon Street
Level 3
Carlton, VIC 3053
Australia
61 3 9824 5254
https://www.immuron.com.au

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 6

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Steven George Lydeamore CPA, M.B.A.	Chief Executive Officer	306,09k	N/D	1968
Dr. Jerry Kanellos Ph.D.	Chief Operating Officer	189,97k	N/D	1961
Mr. Flavio Palumbo	Chief Commercial Officer	191,35k	N/D	1974
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.	CFO & Company Secretary	N/D	N/D	1959
Mr. David Lyon	Head of Marketing	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Governance aziendale

L'ISS Governance QualityScore di Immuron Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.